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Summary
Hyperphosphorylation of the microtubule associated protein,
Tau, is the hallmark of a group of neurodegenerative disorders
known as the tauopathies which includes Alzheimer’s disease.
Precisely how and why Tau phosphorylation is increased in
disease is not fully understood, nor how individual sites modify
Tau function. Several groups have used the Drosophila visual
system as an in vivo model to examine how the toxicity of Tau
varies with phosphorylation status. This system relies on
overexpression of Tau from transgenes but is susceptible to
position effects altering expression and activity of the
transgenes. We have refined the system by eliminating
position effects through the use of site-specific integration.
By standardising Tau expression levels we have been able to
compare directly the toxicity of different isoforms of Tau and
Tau point mutants that abolish important phosphorylation
events. We have also examined the importance of human
kinases in modulating Tau toxicity in vivo. We were able to
confirm that human GSK3b phosphorylates Tau and increases
toxicity but, unexpectedly, we identified that preventing
phosphorylation of Ser404 is a protective event. When
phosphorylation at this site is prevented, Tau toxicity in the
Drosophila visual system is increased in the presence of
GSK3b. Our data suggest that not all phosphorylation events
on Tau are associated with toxicity.
 2013. Published by The Company of Biologists Ltd. This
is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution and reproduction in any
medium provided that the original work is properly
attributed.
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Introduction
The tauopathies are a group of neurodegenerative diseases
characterised by the accumulation of intra-neural aggregates of
the microtubule-associated protein, Tau. They include
Alzheimer’s disease (AD), fronto-temporal lobar degeneration
(FTLD-Tau), Pick’s disease, progressive supranuclear palsy and
corticobasal degeneration. The microtubule-binding properties of
Tau were identified more than 30 years ago but, and despite
intense research, its true physiological role remains unclear, thus
the cellular mechanisms underpinning the tauopathies are also
poorly understood. More recently, additional properties of Tau
have been identified, including an ability to bundle actin
filaments, and multiple Tau-binding partners have been
identified, including tyrosine kinases. Together, these have led
to the suggestion that Tau may act as a signalling scaffold
(reviewed by Morris et al., 2011).
The functions of Tau may be regulated both by alternative
splicing (six isoforms are expressed in the human CNS) and
through a multitude of post-translational modifications. These
include multiple phosphorylation and acetylation events,
glycosylation, ubiquitylation and sumolyation amongst others
(reviewed by Martin et al., 2011). The phosphorylation of Tau
has received the most attention because Tau within
neuropathological aggregates is found primarily in a highly
phosphorylated form (Bue´e et al., 2000; Lee et al., 2001;
Ballatore et al., 2007; Hanger et al., 2009; Iqbal et al., 2009). In
vitro, hyperphosphorylation of Tau reduces its microtubule
binding affinity (Lindwall and Cole, 1984). This leads to an
increase of hyperphosphorylated Tau in the cytosol and a
destabilization of the microtubule network (Cowan et al., 2010;
Feuillette et al., 2010). Both the accumulation of highly
phosphorylated cytosolic Tau and destabilization of the
microtubules are suggested to lead to neurodegeneration
(Cowan et al., 2010; Wu et al., 2011). Yet, increased
phosphorylation of Tau is not necessarily toxic to neurons in
all circumstances as it occurs during fetal development (Yu et al.,
2009) and transiently in hibernating mammals (Arendt et al.,
2003). An alternative view sees elevated Tau phosphorylation as
part of a protective response to oxidative stress rather than a
direct cause of pathology (Castellani et al., 2008; Bonda et al.,
2011). The complex relationship between Tau phosphorylation
and neurodegeneration is also highlighted by observations that
phosphorylation resistant Tau constructs either lose or maintain
their toxicity, suggesting a non-equivalent role for groups of
phosphorylation sites. In Drosophila both TauAP and TauS11A
forms, with 14 or 11 Ser/Thr sites mutated to alanine
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respectively, retain microtubule binding function yet TauAP
loses toxicity while TauS11A retains toxicity (Steinhilb et al.,
2007b; Feuillette et al., 2010; Talmat-Amar et al., 2011). Other
studies have shown alternatively that phosophorylation of Tau at
specific sites can promote microtubule binding or reduce Tau
toxicity (Wada et al., 1998; Feijoo et al., 2005; Thies and
Mandelkow, 2007) while increased binding of Tau to
microtubules may also be deleterious to neurons through
interference with axonal trafficking (Talmat-Amar et al., 2011).
Thus, a precise balance of differential Tau phosphorylation at
individual sites may be required to appropriately regulate levels
of cytosolic or microtubule bound Tau essential for microtubule
dynamics and axon transport.
Since Tau phosphorylation is likely to contribute in some way to
pathology, one therapeutic strategy being followed is to reduce the
phosphorylation load on Tau by targeting Tau kinases (Churcher,
2006; Mazanetz and Fischer, 2007; Brunden et al., 2009). For this
approach to be effective, it is important to identify which of the
many Tau phosphorylation events that have been identified in vitro
are critical for toxicity in vivo and to establish which kinases
phosphorylate Tau in disease states and whether Tau forms
resistant to phosphorylation show reduced toxicity. The scale of
this task is significant because recent studies have identified 45
distinct sites that are phosphorylated on Tau from AD brains
compared with only 17 from healthy brains, with many different
kinases capable of phosphorylating Tau in vitro (Morishima-
Kawashima et al., 1995; Hanger et al., 1998; Hanger et al., 2007;
Hanger et al., 2009; Lebouvier et al., 2009). Moreover, some
phosphorylation events will modify Tau in vitro but not necessarily
in a manner that is physiologically relevant. There is a need,
therefore, for a model system in which individual kinases can be
tested for their ability to alter Tau toxicity in vivo.
Tau-mediated degeneration of photoreceptor neurons in the
Drosophila visual system is a commonly used in vivo model to
study the cell biology of the tauopathies (Wittmann et al., 2001;
Jackson et al., 2002; Muqit and Feany, 2002; Nishimura et al.,
2004; Karsten et al., 2006; Steinhilb et al., 2007a; Khurana, 2008;
Chatterjee et al., 2009). Typically, human Tau is expressed
ectopically in the developing Drosophila brain or visual system,
resulting in neurodegeneration that bears several hallmarks of the
tauopathies, including age dependency, abnormally
phosphorylated Tau and, in some cases, Tau aggregates (e.g.
Wittmann et al., 2001; Jackson et al., 2002; reviewed by
Gistelinck et al., 2012). The powerful genetics of Drosophila can
be employed to identify endogenous genes that are required for
tau-mediated degeneration or can modify the degree of
degeneration mediated by human Tau. Using this approach,
several Drosophila kinases, including the homologues of GSK3b,
MARK, cdk5, JNK and PKA, have been implicated in Tau
toxicity (Wittmann et al., 2001; Jackson et al., 2002; Shulman
and Feany, 2003; Chau et al., 2006; Steinhilb et al., 2007a;
Steinhilb et al., 2007b; Chatterjee et al., 2009).
Following our studies of Tau phosphorylation in AD post-
mortem brain (Hanger et al., 1998; Hanger et al., 2007), we were
interested to determine whether the Drosophila photoreceptor
model could be used to assess the roles of human kinases in
mediating neurodegeneration in vivo and to identify particular
phosphorylation events on Tau that are important for toxicity.
Transgene expression in Drosophila is affected by positional
effects on transgene activity which complicate comparisons of
the toxicity mediated by different isoforms or mutant forms of
human Tau. To overcome this, we used an alternative
methodology to express Tau where Tau transgenes are targeted
to pre-determined sites in the Drosophila genome to control for
any positional effects and permit direct comparisons of toxicity.
We sought to confirm the importance of GSK3b as a pathological
kinase in vivo, both individually and in combination with CK1d
or DYRK1A, both of which could act as priming kinases for
GSK3b by phosphorylating Tau residues adjacent to GSK3b
target sites (reviewed by Doble and Woodgett, 2003). CK1d is
highly overexpressed in AD brain (Ghoshal et al., 1999) and is
tightly associated with PHF Tau (Kuret et al., 1997). DYRK1A is
both overexpressed in AD brain material and duplicated in the
critical region of chromosome 21 in Down’s syndrome which is
associated with early onset AD (Kimura et al., 2007). We were
able to confirm the importance of GSK3b for toxicity in vivo, but
found little role for priming kinases in this system. Surprisingly,
we identified a GSK3b-mediated phosphorylation event that
seems to be protective. We also found that, in contrast to previous
work, the R406W mutation in Tau associated with FTLD-Tau has
no effect on toxicity in this system.
Results
Tau-mediated degeneration in transgenic flies is modified by
position effects
We sought to use Drosophila as a model to assess the roles of
human kinases to generate toxic forms of Tau and to identify the
particular phosphorylation events on Tau responsible for toxicity.
Previous studies of human Tau toxicity in Drosophila have used
transgenic lines generated by P-element mediated transgenesis
(Wittmann et al., 2001; Jackson et al., 2002; Nishimura et al.,
2004; Steinhilb et al., 2007a; Steinhilb et al., 2007b; Chatterjee et
al., 2009) where constructs containing human Tau cDNA are
inserted at random into the Drosophila genome (Spradling and
Rubin, 1982). Expression of Tau is achieved using the UAS/
GAL4 system or by use of a tissue specific promotor. However
variable levels of expression results from the same Tau construct
inserted at different genomic locations. This position-dependent
expression is a well-characterised phenomenon of P-element
mediated transgenesis in Drosophila and, whilst this can be
exploited to obtain a range of expression levels (Wilson et al.,
1990), it may limit the ability to directly compare the toxicity of
variant forms of the transgene. We investigated the extent to
which Tau toxicity can vary due to positional effects resulting
from random insertion of the same transgene. We generated five
different random insertions of UAS-2N4R Tau and used GMR-
GAL4 to drive Tau expression in the developing visual system
from one copy of the transgene. The disruption of the regular,
crystalline array of ommatidia in the adult compound eye ranged
from mild (e.g. line 4) to severe (e.g. line 3) (Fig. 1A).
We identified the genomic insertion site of UAS-Tau for each
line (supplementary material Table S1). Four of the five lines
(lines 1, 2, 4, and 5) were homozygous viable insertions and none
of these showed an eye phenotype in the absence of the GMR-
GAL4 driver. Line 3 exhibited the most severe degeneration
(Fig. 1). This line contained Tau inserted into the l(3)87Df gene,
and was lethal when homozygous. To exclude the possibility that
the severe degeneration apparent in line 3 was due to a genetic
interaction between Tau and l(3)87Df gene, which encodes a
probable chaperone, we used GMR-GAL4 to express Tau
from the mildly disruptive line 1 locus in a genetic
background heterozygous for an allele of l(3)87Df. No increase
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in degeneration resulted, excluding the possibility that l(3)87Df
plays a role in Tau-mediated degeneration (supplementary
material Fig. S1). We concluded that the Tau-mediated
degeneration is highly dependent on positional effects and we
would need to control for these if we were going to compare the
toxicity of different forms of Tau.
The amount of Tau protein does not correlate with degeneration
To determine the relationship between the level of disruption to
the eye in the differing transgenic lines and Tau protein
expression, we quantified the amount of Tau expressed in each
line in Drosophila heads normalised to b-actin (Fig. 1B,C). We
detected significantly less Tau protein in line 3, compared to the
other lines, despite this line displaying the most severe
degeneration. The amounts of Tau protein present in lines 1, 2,
4, and 5 were equivalent to each other, despite differences in the
degree of disruption to the eye (Fig. 1C). The reduced level of
Tau protein in the lines with greater levels of disruption may
potentially be due to increased numbers of dying or dead cells.
To circumvent this we used qPCR to measure transcript levels of
each Tau transgene earlier in the development of the visual
system, within late third instar larval eye imaginal discs, prior to
onset of degeneration. We controlled for the number of cells
expressing GMR-GAL4 (and therefore Tau) by recombining
UAS-GFP with GMR-Gal4 to drive the expression of GFP.
Normalisation of the Tau transcript levels to that of GFP for each
line revealed significantly increased Tau transcription in the
highly degenerate line 3 compared to all of the other Tau
insertion lines (Fig. 1D). Lines 1, 2, 4, and 5 each express
approximately equivalent amounts of Tau mRNA and protein,
despite variation in the levels of Tau toxicity apparent in each
line. Line 3 expresses significantly more Tau mRNA which
correlates with the more severe degenerate phenotype, suggesting
the lower levels of Tau protein in adults is a consequence of
increased cell loss. Thus, the level of toxicity mediated by 2N4R-
Tau driven from differing transgenes varies significantly and is
influenced by positional effects. We could not be confident that
protein or mRNA levels would predict toxicity sufficiently
accurately to be used as a reliable method for selecting
comparable insertion lines.
Site-specific integration of transgenes eliminates the effects of
positional variation
To overcome the problem of positional effects on Tau
expression, we turned to the wC31 system that allows site
specific integration of Drosophila transgenes at specific
‘‘landing’’ sites in the genome (Groth et al., 2004). We
integrated UAS-2N4R Tau at five different landing sites
spread across chromosomes II and III (insertion sites at 51C,
68A, 68C, 86F and 96E). After crossing to GMR-GAL4 driver
flies, toxicity in the eyes was assessed (Fig. 2A). In two cases
(51C and 68E; Fig. 2A, upper row) there was very little
disruption of the crystalline array of ommatidia; in three others
(68A, 86F and 96E; Fig. 2A, lower row) disruption was
moderate. In none of the lines was disruption seen to the level
of any of our randomly integrated lines (cf. Fig. 1). We
quantified Tau transcript expression in eye discs from two of the
five site-specific lines, 68A and 86F, relative to GFP, as before.
As expected, Tau is expressed at significantly lower levels in
both of these lines. Tau expression levels in the targeted
insertion lines was approximately half of the level in the random
insertion lines 1 and 2 and considerably lower than the highly
degenerate line 3 (Fig. 2B). To check reproducibility of the
landing sites, we generated an additional independent line with
UAS-2N4R Tau inserted at the 68A locus. This second insertion
generated an identical eye phenotype to the initial 68A
transgenic when expression was driven with GMR-GAL4
(data not shown).
Fig. 1. Position effect causes variations in Tau-mediated toxicity in the
Drosophila eye. (A) Scanning electron micrographs of Drosophila eyes. The
regular array of ommatidia of the compound eye is disrupted by overexpression
of Tau to a variable degree. The GMR-gal4 driver was mated to wild-type
(control) or UAS-2N4R Tau flies. Five different randomly inserted UAS-lines
were assayed. (B, C) Quantitative Western blotting of Tau levels in adult
Drosophila heads from GMR-gal46UAS-2N4R Tau flies. B. Blot probed with
anti-total Tau and anti-b-actin. (C) Quantification of Tau protein levels
normalised to actin. Recombinant Tau was included to permit normalisation
between blots. (D) Tau transcript levels in brain and eye discs from third instar
larvae before degeneration occurs. Tau transcripts were normalised to
membrane GFP expressed from the GMR-gal4 chromosome after
recombination (see Materials and Methods).
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Using site-specific insertion lines, R406W mutation does not
enhance the toxicity of Tau
We used the wC31-mediated site-specific insertion to test the
contribution of specific residues within Tau to cause toxicity in
vivo. The R406W mutation in Tau is associated with some cases
of autosomal dominant FTLD-Tau (Hutton et al., 1998) and has
been reported to be more toxic than wild-type Tau when
overexpressed in Drosophila (Wittmann et al., 2001; Jackson et
al., 2002; Khurana et al., 2006). The R406W mutation affects the
ability of Tau to regulate microtubule dynamics in vitro (Bunker
et al., 2006) and impairs axonal transport in mice when
overexpressed at high levels (Zhang et al., 2004) and may also
affect the phosphorylation of Tau by specific kinases (Mack et
al., 2001). We used GMR-GAL4 to drive expression of the 2N4R
and 0N4R wild-type and R406W Tau isoforms from constructs
inserted into the 68A locus. We found that there were no
differences in toxicity between unmodified 0N4R or 2N4R Tau
and those containing the R406W point mutant when expressed
from the same insertion site, in contrast to the severe increase in
toxicity in the eye reported previously for the R406W mutation
(Wittmann et al., 2001; Jackson et al., 2002; Nishimura et al.,
2004) (Fig. 3A, upper panels). In parallel, we examined the eye
phenotype of flies overexpressing 0N4R Tau R406W from the
randomly inserted construct generated by the Feany lab and used
in several previous studies (Wittmann et al., 2001; Jackson et
al., 2002; Nishimura et al., 2004) and confirmed this line
generated a much stronger phenotype in the eye (Fig. 3B). We
quantified transcript expression in larval eye discs and
normalised expression to that of the strongest 2N4R Tau
random insertion, line no. 3 (Fig. 3C). This revealed that each of
the four Tau isoforms were expressed from the 68A site at
similar levels, as expected (no significant differences were
observed; Fig. 3C), but notably, expression from the 68A
insertion site was approximately half that from four of the
five randomly integrated lines we generated. The 0N4R Tau
R406W line was expressed at a level twice that of the lines
inserted at 68A and comparable to the level seen for most of our
random insertions (Fig. 3C). We wondered whether Tau
expression from the 68A insertions was below a threshold
needed to observe any differential toxicity. We increased
expression by combining GMR-GAL4 with double the copy
number of the 68A UAS-Tau insertion in homozygous animals.
As expected, the eye phenotype worsened in each case (Fig. 3A,
lower panels) but the R406W variants of both 2N4R and 0N4R
Tau continued to show similar toxicity to the non-mutated
forms.
Fig. 2. Site-specific insertions of UAS-2N4R Tau mediate lower levels of
toxicity. UAS-2N4R Tau was inserted into five specific genomic landing sites
by wC31-mediated integration. (A) Light micrographs of adult eyes from GMR-
gal46wild-type (control) or UAS-2N4R Tau crosses. Areas of the eye
displaying significant disruption are highlighted with dashed lines. (B) Tau
transcript levels driven by GMR-gal4 from two site-specific UAS insertions
normalised to our random insertion line 3.
Fig. 3. No increase in Tau-mediated toxicity caused by the R406W
mutation. (A) GMR-gal4 driving expression from the 68A integration site of
2N4R or 0N4R Tau with or without the R406W mutations. Upper row: one
copy of the UAS-insert. Lower row: two copies of the UAS-insert. GMR-gal4 is
heterozygote in all cases. The R406W mutation does not increase toxicity.
(B) GMR-gal4 driving 0N4R Tau R406W from a randomly inserted UAS-line
generated by the Feany lab (Wittmann et al., 2001). (C) Tau transcripts levels
driven by GMR-gal4 normalised to our random insertion line 3.
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Assay of human GSK3b activity for Tau toxicity
The low level of Tau overexpression from our 68A insertions
results in moderate toxicity and provides a baseline to investigate
factors that increase toxicity. This level of expression may be
representative of human disease where Tau expression is not
elevated.
Several groups have previously investigated phosphorylation
of exogenous human Tau by endogenous Drosophila kinases
(Nishimura et al., 2004; Steinhilb et al., 2007a; Steinhilb et al.,
2007b). A key role has been reported for Shaggy, the Drosophila
homologue of GSK3b, consistent with the suggestion that
GSK3b is a major pathological kinase in human tauopathies
(Hanger et al., 1992; Lovestone et al., 1994; Lucas et al., 2001;
Huang and Klein, 2006). We investigated whether Shaggy
overexpression could similarly increase Tau toxicity in our
targeted expression system. We used the GMR-GAL4 driver to
express Shaggy from a UAS-shaggy transgene in the presence or
absence of 2N4R Tau inserted at the 68A locus. We found that,
whereas expression of Shaggy alone caused mild disruption of
the ommatidia, co-expression with 2N4R Tau resulted in
increased eye disruption (Fig. 4A, dashed area highlights
severe disruption and glazing of the eye). The ommatida were
more severely disrupted and patches of pigment loss and glazing
were visible in the eyes of the Shaggy and Tau expressing flies.
Thus, Tau-mediated toxicity can be increased by co-expression of
human Tau with Drosophila GSK3b, even at low levels of Tau
expression.
In order to examine whether human GSK3b (hGSK3b) could
also enhance Tau-mediated toxicity in Drosophila, we first
confirmed that hGSK3b was capable of phosphorylating human
Tau in Drosophila cells. When hGSK3b was co-expressed with
human 2N4R Tau in Drosophila S2 cells, we identified hGSK3b-
mediated phosphorylation events using PHF1, AT8, AT270 and
AT100 antibodies which recognise specific Tau phospho-
epitopes (supplementary material Fig. S2). We next generated
four UAS-hGSK3b transgenic lines by random insertion and
found each line was expressed to varying amounts (Fig. 4B) yet
expression of hGSK3b alone did not disrupt the ommatidial
structure (Fig. 4A, upper panels). When hGSK3b expression was
driven together with 2N4R Tau inserted in the 68A locus an
enhanced disruption of the eye occurred (Fig. 4A, lower panels).
The degree of enhancement was dependent on the level of
GSK3b expression from each transgene (Fig. 4A,B). hGSK3b
line 1 has the highest expression and generated the greatest
toxicity when expressed with Tau, all subsequent experiments
were performed using this hGSK3b line 1. We examined whether
Fig. 4. Co-expression of human GSK3b increases Tau-mediated toxicity. (A) Light micrographs of adult fly eyes. Drosophila (Shaggy) or hGSK3b was driven in
the visual system under the control of GMR-gal4 either alone (upper row) or alongside 2N4R Tau from the 68A insertion site. Shaggy expression alone causes
disruption of eye development but hGSK3b does not. Co-expression of GSK3b increases the toxicity of Tau. Areas of the eye displaying significant disruption
including substantial areas of glazing are highlighted with dashed lines. (B) Relative expression of hGSK3b driven from four random UAS-insertions. Higher
transcript levels correspond to higher Tau-mediated toxicity. (C) Increased toxicity does not correlate with a change in solubility of Tau. Tau in sarcosyl-soluble and -
insoluble fractions was quantified by western blotting with or without co-expression of hGSK3b.
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the increased Tau toxicity caused by hGSK3b was a consequence
of changes to Tau solubility since altered solubility of Tau is
associated with neurodegenerative tauopathies (Lewis et al.,
2000; Ishihara et al., 2001; Zhukareva et al., 2002; Hirata-Fukae
et al., 2009). Sarcosyl fractionation is a commonly used method
to assay Tau solubility (Lewis et al., 2000; Zhukareva et al.,
2002). We extracted sarcosyl-soluble and sarcosyl-insoluble
fractions from Drosophila heads and found no change in the
ratio of soluble to insoluble Tau in these fractions when hGSK3b
was co-expressed together with Tau in Drosophila (Fig. 4C).
GSK3b-mediated phosphorylation events on Tau
We used antibodies to four phospho-epitopes, in addition to total
Tau to examine the effects of hGSK3b expression on
phosphorylation of Sarcosyl-soluble and Sarcosyl-insoluble
extracts in the Tau transgenic flies. Three of the antibodies
(AT270, PHF1, and AT8) recognise known GSK3b target sites in
Tau (Thr181, Ser396/404, and Ser202/Thr205, respectively),
whereas labelling by antibody AT100 requires phosphorylation
of both Thr212 and Ser214 by GSK3b in combination with
another kinase (Sato et al., 2002). Soluble and insoluble Tau was
readily detected in the heads from Drosophila expressing the
2N4RTau transgene inserted into the 68A landing site (Fig. 5A–
D). We found at the levels of Tau expression seen in our system
neither soluble or insoluble Tau were phosphorylated appreciably
on Ser396/Ser404 by endogenous Drosophila kinases but both
fractions were phosphorylated when hGSK3b was co-expressed
(Fig. 5A,E,F; PHF1). Residue Thr181 on Tau was
phosphorylated in both soluble and insoluble fractions by
endogenous kinases and this phosphorylation was significantly
increased by hGSK3b (Fig. 5B,E,F; AT270). In contrast, Ser202/
Thr205 was phosphorylated by endogenous kinases but
phosphorylation at this epitope was not increased by hGSK3b
(Fig. 5C,E,F; AT8). Phosphorylation of Thr212 and Ser214 was
Fig. 5. Tau phospho-epitopes phosphorylated by human
GSK3b in the Drosophila visual system. Sarcosyl-soluble
and -insoluble Tau fractions were purified from fly heads
overexpressing 2N4R Tau from the 68A locus with or
without hGSK3b. Four phospho-specific antibodies were
used to identify specific phosphorylation events mediated
by hGSK3b in vitro.
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barely detectable in soluble Tau and was absent from insoluble
Tau. Furthermore, this epitope was not generated by co-
expression of hGSK3b (Fig. 5D; AT100). Thus, Tau residues
Ser202/Thr205 and Thr212/Ser214 are not targets for hGSK3b in
vivo, at least in Drosophila, but phosphorylation of Thr231 and
Ser396/Ser404 is substantially increased in this system.
No role for GSK3-priming kinases in mediating Tau toxicity in
the Drosophila eye
Our failure to detect phosphorylation of Thr212/Ser214 by
hGSK3b to generate the AT100 epitope may indicate a
requirement for priming at adjacent upstream Ser residues by
an additional kinase (Doble and Woodgett, 2003). One candidate
is casein kinase 1d (CK1d) which acts co-operatively with
GSK3b on some substrates (Zeng et al., 2005). CK1d is highly
overexpressed in AD brain (Ghoshal et al., 1999) and our
previous work has indicated a potential role for this kinase in
aberrant phosphorylation of Tau (Hanger et al., 2007). We also
wished to see if dual-specificity tyrosine phosphorylation
regulated kinase 1A (DYRK1A) would act similarly. DYRK1A
phosphorylates Tau in vitro and acts as a priming kinase for
GSK3b (Woods et al., 2001). The DYRK1A gene lies within the
critical region on chromosome 21 and is duplicated and
overexpressed in Down Syndrome (DS). DS patients have a
high incidence of early onset AD and one possible cause is
hyperphosphorylation of Tau by the overexpressed DYRK1A
(Ryoo et al., 2007; Liu et al., 2008). We generated transgenic
UAS-human CK1d and UAS-rat DYRK1A lines by random
insertion. CK1d was truncated after amino acid 371 because the
shorter form is constitutively active. The kinases were expressed
alongside Tau either with or without hGSK3b but the toxicity
was not enhanced in any situation (supplementary material
Fig. S3).
GSK3b-mediated S404 phosphorylation is protective
To determine which, if any, of the hGSK3b sites on Tau that we
confirmed as phosphorylated in vivo are essential for increased
toxicity, we replaced the individual residues, Ser202, Ser205,
Thr212 or Ser404 in 2N4R Tau with non-phosphorylatable
alanine. In a fifth mutant, all four of these residues were
substituted by alanine (termed Tau4xA). We examined the effect
of these mutations on the ability of hGSK3b to phosphorylate
2N4R Tau in Drosophila cells. When 2N4R Tau is expressed
in cells, multiple Tau bands were detected using a
phospho-independent antibody. These likely correspond to
different phosphorylated forms mediated by endogenous
kinases. Co-expression of hGSK3b resulted in a retardation of
the Tau bands in the gel, indicating increased phosphorylation
(Fig. 6A; see 2N4R wt). Mutating Tau at S202, S205 or T212 had
no effect on the banding pattern of Tau, either with or without co-
expression of hGSK3b (Fig. 6A). In contrast, introducing the
S404A mutation abolished the slowest migrating Tau bands,
suggesting that this site is an important target of hGSK3b. The
4xA form of Tau carrying each of the four point mutations
Fig. 6. Phosphorylation of S404 by human GSK3b is
protective in the Drosophila visual system. (A,B) Wild-
type or point mutated forms of human 2N4R Tau were
expressed in Drosophila S2 cells with or without myc-
tagged hGSK3b. (A) Multiple bands representing
differentially phosphorylated forms of Tau were detected
between 60 and 70 kDa with a phospho-independent
antibody. Co-expression of hGSK3b retards Tau mobility,
indicative of increased phosphorylation load but this is
absent in the Tau S404A or 4xA mutants. Recombinant Tau
was included as a positive control for anti-Tau. (B) The
pS396/pS404 epitope recognised by PHF1 is
phosphorylated by hGSK3b but not by endogenous kinases.
Phosphorylation is absent in the Tau S404A and the 4xA
mutants. (C) Light photomicrographs of adult fly eyes.
GMR-gal4 was used to express wild-type 2N4R Tau or
S202A, T205A, T212A or S404A or Tau4xA Tau point
mutants (top row). hGSK3b was co-expressed with each
Tau isoform (bottom row). Areas displaying severe
disruption to eye development including glazing and loss of
pigmentation are highlighted by dashed lines. The S404A
and 4xA mutant display increased toxicity when co-
expressed with hGSK3b.
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showed an identical reduction in phosphorylation and, as
expected, the PHF1 antibody, which recognises the pS396/
pS404 epitope on Tau, detected phosphorylation by hGSK3b on
WT, S202A, S205A and T212A forms of Tau not in the S404A
and 4xA mutant forms (Fig. 6B).
We made transgenic flies by inserting the mutant Tau
constructs into the same 68A locus as before to examine the
resistance of each of these mutations to hGSK3b-induced
toxicity. When each of the single point mutations, Tau4xA, or
wild-type Tau, was expressed in the Drosophila visual system,
toxicity was equivalent. Each resulted in mild disruption of
ommatidia (Fig. 6C, also cf. Fig. 2). Co-expression of three of
the Tau mutants, Tau S202A, T205A or T212A, with hGSK3b,
resulted in no changes in toxicity (Fig. 6). However, hGSK3b
expression unexpectedly increased the amount of degeneration
observed with either TauS404A or Tau4xA. The eyes had a
greater degree of external disorganisation and extensive patches
of depigmentation indicative of increased toxicity (Fig. 6;
depigmented areas marked by dashed lines). This result
indicates that phosphorylation of Ser404 in Tau by hGSK3b
modulates the toxicity of Tau in vivo but in this system,
phosphorylation may not increase Tau toxicity but instead may
be protective against degeneration.
Discussion
Hyperphosphorylated Tau is associated with a number of
neurodegenerative diseases, strongly suggesting that
disregulated phosphorylation of Tau leads to neural pathology.
In order to progress towards effective therapies it is key to
identify which of the many Tau phosphorylation events are
critical for toxicity in vivo and to establish which kinases
phosphorylate Tau to cause disease. Previous studies have used
Drosophila to identify endogenous kinases that increase Tau
toxicity (Jackson et al., 2002; Mudher et al., 2004; Nishimura et
al., 2004; Chatterjee et al., 2009). We were interested to
determine whether the Drosophila photoreceptor model could
be used to assess the roles of human kinases in mediating
neurodegeneration in vivo and to identify particular
phosphorylation events on Tau that are important for toxicity.
Use of this model requires that the individual transgenic lines
generated to test manipulated forms of Tau be expressed
identically. However, we and others have demonstrated that
Tau transgenes randomly integrated within the Drosophila
genome produced variable levels of expression. This presented
a significant challenge in seeking to identify the contribution to in
vivo toxicity of Tau phosphorylation events mediated by human
kinases. In previous studies, transgenic flies were selected for
comparable Tau expression based on western blot analysis
(Wittmann et al., 2001; Steinhilb et al., 2007a; Steinhilb et al.,
2007b). However, we have found a highly degenerate eye
phenotype was associated with reduced Tau protein, presumably
due to cell death. Rather, the toxicity correlated with the level of
RNA expression at earlier developmental stages, before cell
death was apparent. We demonstrated that the toxicity mediated
by different forms of Tau was difficult or impossible to compare
even after selecting lines with comparable protein or mRNA
expression levels because even small changes in Tau transcript
level resulted in quite variable degrees of toxicity. We concluded
that, using the standard method of generating transgenic flies that
is susceptible to position effects, it would be difficult to be
certain that changes in toxicity mediated by different forms of
Tau were due to the properties of the Tau protein itself rather
than subtle changes in expression level.
Controlling for integration site is necessary to assess
Tau toxicity
To remove any possible confounding positional effects generated
by random integration of Tau transgenes, we adopted wC31-
mediated site-specific integration to standardise the genomic
integration locus (Groth et al., 2004). We found that, as expected,
Tau transgenes inserted into the same locus resulted in the
equivalent expression of tau transcript. We selected Drosophila
landing sites that expressed Tau at levels low enough to produce
only a mild disruption of the structure of the ommatidia of the
eye. This has a major advantage because, although the ratio of
4R:3R Tau varies between tauopathies (Ingelsson et al., 2007),
Tau is not thought to be significantly overexpressed in AD. Thus,
our model system, in which Tau is not highly overexpressed, may
be more useful for uncovering mechanisms underlying Tau
toxicity in disease.
Using site-specific integration, we examined the toxicity of
two Tau isoforms (0N4R and 2N4R), with or without a point
mutation, R406W, which is found in some autosomal dominant
forms of FTLD-Tau (Hutton et al., 1998). Previous studies by
others have reported a strong, highly disrupted eye phenotype
when 0N4R R406W Tau is overexpressed in the Drosophila
visual system, indicating enhanced toxicity (Wittmann et al.,
2001; Jackson et al., 2002; Nishimura et al., 2004). We confirmed
the increased toxicity of 0N4R Tau R406W in vivo using a
previously generated strain with a randomly integrated Tau
transgene (Wittmann et al., 2001). However, we found that, when
we controlled for the integration site and reduced Tau
overexpression using wC31-mediated site-specific integration,
we failed to see any increase in toxicity caused by this mutation.
We were also unable to detect any difference in toxicity
generated by expression of the 0N4R and 2N4R Tau isoforms.
Doubling the copy number of each of the UAS-transgenes
increased the amount of toxicity observed, as expected from the
increased expression of Tau. However, despite two copies of
UAS-Tau increasing Tau expression to a level similar to that of
the 0N4R Tau R406W line developed previously (Wittmann et
al., 2001), the R406W mutation still had no effect on the
organisation of the Drosophila eye. When we controlled for
positional effects, our results suggest that the R406W mutation
does not have a significant effect on Tau-mediated toxicity.
Interestingly, this conclusion is in agreement with previous
studies assaying the effect of FTLD-Tau-associated point
mutations on the microtubule-binding properties of Tau
(Delobel et al., 2002; Bunker et al., 2006). In an in vitro study
using purified microtubules (Bunker et al., 2006) and an in vivo
assay in Xenopus oocytes (Delobel et al., 2002), Tau R406W
displayed only subtle differences in microtubule-binding
compared to wild-type Tau. Taken together, these findings are
consistent with the late onset of symptoms and slow disease
progression observed in FTLD-Tau patients carrying the R406W
Tau mutation (Heutink, 2000).
GSK3b-mediated Tau toxicity is enhanced by S404A
GSK3b is a key candidate pathological Tau kinase in AD
(Hanger et al., 1992; Lovestone et al., 1994; Lucas et al., 2001) to
the extent that lithium and other GSK3b inhibitors have been
trialled clinically for AD (reviewed by Mangialasche et al.,
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2010). GSK3b can phosphorylate many residues on Tau in vitro
but it is not yet clear how each phosphorylation event contributes
to Tau toxicity (Hanger et al., 2007) or whether all sites increase
toxicity. We examined the role of priming kinases as a possible
level of regulation. However, we were unable to detect any
significant role for CK1d or DYRK1A on Tau toxicity in this
model system. Although hGSK3b did increase Tau toxicity,
in our study it was not possible to identify a specific
phosphorylation event that is responsible for this increased
toxicity, suggesting that phosphorylation at multiple residues
generate toxicity confirming previous observations investigating
endogenous kinases (Steinhilb et al., 2007a; Steinhilb et al.,
2007b; Chatterjee et al., 2009). Unexpectedly we found that
phosphorylation of S404 in Tau appeared to be protective when
co-expressed with hGSK3b, and substitution of S404 with
alanine resulted in an enhanced toxicity compared to
expressing either S404A or hGSK3b alone. A previous study
examining the role of phosphorylation for Tau-mediated toxicity
in the Drosophila eye identified that the double mutant S396A/
S404A did not affect Tau toxicity (Steinhilb et al., 2007a)
produced from endogenous kinases. We also found that S404A
did not affect toxicity when acted on by endogenous kinases but
see an enhancement of toxicity when S404A Tau was expressed
together with hGSK3b together. We did not observe any
phosphorylation of Ser396/Ser404 by endogenous Drosophila
kinases but this epitope was phosphorylated when hGSK3b was
co-expressed with Tau. Our results contrast therefore with the
previous study, in which phosphorylation by endogenous kinases
was detected at this site (Steinhilb et al., 2007a). This difference
may be due to the increased toxicity of Tau in the previous study
due to elevated Tau expression, which could potentially affect the
recognition of Tau by endogenous kinases.
Importantly, although increased Tau phosphorylation is
considered by many to be pathological, our observations
indicate that some phosphorylation events may have a
protective effect. Previous studies have also indicated that
phosphorylation of Tau may reduce toxicity (Thies and
Mandelkow, 2007). The PHF1 epitope (comprising pSer396
and pSer404) appears to be dynamically regulated by stress.
Phosphorylation of these Tau residues is affected in various stress
situations in vivo, including post-ischemic injury (Wen et al.,
2004; Gordon-Krajcer et al., 2007) and following anaesthesia-
induced hypothermia (Planel et al., 2007). In vitro, both
phosphorylation (Go´mez-Ramos et al., 2003) and
dephosphorylation (Zambrano et al., 2004) of Ser396/Ser404
have been reported under conditions of oxidative stress. These
data presumably reflect dynamic regulation: in ischaemic injury,
Ser396/Ser404 becomes almost completely dephosphorylated,
followed by a rapid increase in phosphorylation (Gordon-Krajcer
et al., 2007). The phosphorylation of Ser396/Ser404 in
neuroblastoma cells treated with lipid peroxidising agents can
be blocked by inhibitors of either GSK3b or the stress-activated
kinase p38, but not by cyclin-dependent kinase-5, supporting the
view that phosphorylation of this epitope could be part of a co-
ordinated neuronal stress response. It has been argued that
increased Tau phosphorylation is a protective response to stress,
rather than a primary cause of neuronal toxicity (Castellani et al.,
2008; Bue´e et al., 2010), a view supported by evidence that
expression of hypophosphorylated forms of Tau can also cause
neurotoxicity (Chatterjee et al., 2009; Talmat-Amar et al., 2011).
The inability to phosphorylate Ser404 combined with increased
GSK3b activity may lead to a pattern of Tau phosphorylation that
modifies its microtubule binding properties in such a way that
toxicity is increased, potentially by generating a form that
irreversibly binds microtubules. Alternatively GSK3b may
modify additional components that contribute to Tau toxicity via
a mechanism that is sensitive to the phosphorylation load on Tau.
GSK3b expression can increase the toxicity of some but not all
phosphorylation resistant forms of Tau, suggesting an interplay
between Tau phosphorylation status and further kinase dependent
components. Our modification of the Drosophila in vivo toxicity
model may help to decipher the different roles of specific Tau
phosphorylation events leading to changes in Tau toxicity.
Materials and Methods
Drosophila husbandry and stocks
Flies were maintained on standard cornmeal agar medium. Crosses were
maintained at 18 C˚ or 25 C˚ on semi-defined rich ‘‘German food’’. Medium
recipes are available from the Bloomington Drosophila Stock Centre website.
Transgenic flies were generated by standard P-element mediated transgenesis or
wC31-mediated transgenesis by BestGene Inc. (Chino Hills, CA, USA) or
GenetiVision (Houston, TX, USA). All transgenic flies produced were confirmed
by sequencing and Splinkerette PCR was used to identify genomic DNA flanking
regions (Potter and Luo, 2010). The control strain used for all experiments was an
isogenic w1118 line (Vienna Drosophila RNAi Center). Details of genetic markers
and balancer chromosome are described at Flybase (http://flybase.org). GMR-
GAL4 was used to drive expression of UAS-Tau and UAS-kinases in the visual
system as previously described (Tuxworth et al., 2009).
Molecular biology
Generation of UAS constructs
Full length open reading frames (ORFs) of cDNAs for Tau and each kinase were
amplified with proof-reading Taq polymerase, cloned into pENTR (Invitrogen)
and verified by sequencing. Constructs were recombined into the Murphy
collection of Destination vectors supplied by the Drosophila Genomic Resource
Centre (Bloomington, IN). The kinases were epitope-tagged with Myc or Flag
sequences, while Tau was not tagged.
Site-directed mutagenesis of Tau
The ORF of 2N4R human Tau cloned into pTW was mutated using the
QuikChange Multi kit (Stratagene) and confirmed by sequencing.
cDNA synthesis
RNA was extracted from 5–10 adult fly heads using Tri Reagent (Sigma) and used
immediately for cDNA synthesis with the ImProm-IITM Reverse Transcription
System (Promega) following the manufacturer’s instructions. 500 ng RNA was
used per reaction.
qPCR
Quantitative PCR was performed by QStandard (http://www.qstandard.co.uk).
Transcript levels for the following genes were quantified: Drosophila actin5c
(CG4027), Drosophila GAPDH2 (CG8893), Drosophila EIF-4a (CG9075), mouse
CD8a (geneID: 12525), human Tau (geneID: 4137).
Imaging of fly eyes
Whole flies were processed for scanning electron microscopy or light microscopy
and imaged as described (Tuxworth et al., 2009).
Biochemistry
Homogenisation of Drosophila heads
Fly heads were used as material for qPCR and biochemistry. Whole flies were
snap-frozen in liquid nitrogen and shaken at 6.5 m/s for 20 secs in a FastPrep24
homogeniser (MP Biomedical) to decapitate. Fly heads were separated from
thoraces and abdomens by shaking through a fine sieve.
A two-stage, neutral-alkaline extraction procedure was used to maximise
recovery of Tau protein. Fly heads were homogenised (20 heads/100 ml) in 100 ml
ice-cold homogenisation buffer (50 mM Tris-HCl; 300 mM NaCl; 1% v/v b-
mercaptoethanol, protease and phosphatase inhibitor cocktails [Calbiochem]),
pH 6.8, and garnet beads in a FastPrep24 homogeniser (MP Biomedicals). Heads
were homogenised twice at 6.5 m/s for 20 s and centrifuged at 20,000 g for
10 min at 4 C˚. The supernatant was removed and stored on ice. A second
homogenisation was then performed by adding 100 ml of ice-cold homogenisation
buffer at pH 9.2 to the pellet and centrifuging as above. The supernatants were
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combined, the pH adjusted to 8.0 and then centrifuged at 20,000 g for 30 min at
4 C˚. The final supernatant was stored at 280 C˚.
Sarcosyl-solubility of Tau
Ice-cold Tris buffer (10 mM Tris-HCl, pH 7.5, 800 mM NaCl, 1 mM EGTA, pH 8.0,
10% w/v sucrose, supplemented with protease and phosphatase inhibitor cocktails)
was added to the fly heads (30 heads/60 ml buffer) and garnet beads. Fly heads were
homogenised three times at 6.5 m/s for 20 s as above, then centrifuged at 1,000 g for
5 min at 4 C˚. The supernatant was removed and stored at280 C˚ and referred to as the
sarcosyl-soluble fraction. N-lauroylsarcosinate (Sigma) was added to the pellet to give
a final concentration of 1% (w/v) and the suspension was incubated for 1 h at ambient
room temperature with gentle shaking. The suspension was centrifuged at 100,000 g
for 1 h at 4 C˚. The insoluble pellet was resuspended in 50 mM Tris-HCl, pH 7.5,
stored at 280 C˚ and referred to as the sarcosyl-insoluble fraction.
Western blotting
SDS-PAGE, Western blotting, membrane blocking and probing were all performed
by standard protocols. The membrane used was supported nitrocellulose (BioRad)
which was blocked for 1 h in 5% milk in Tris-buffered saline (TBS) without
Tween-20. Antibodies were diluted in 5% milk in TBS, 0.1% Tween-20 (TBST).
Blots were washed with TBST, followed by two washes in TBS without Tween
prior to imaging.
Antibodies used
Primary antibodies raised against: total human Tau (phosphoinsensitive), used at
1/10,000 (Dako); PHF1 human Tau pS396/pS404, used at 1/5,000 (gift of P.
Davies, Albert Einstein College of Medicine, NY); AT8 human Tau pS202/pT205
at 1/2,000 (Innogenetics); Tau1 human Tau 197–208 at 1/1,000 (Chemicon);
AT100 human Tau pT212/pS214 at 1/1,000 (Innogenetics); AT270 human Tau
pT181 at 1/1,000 (Innogenetics); 9E10 c-Myc at 1/1,000 (Santa Cruz); M2 Flag-
tag at 1/1,000 (Sigma); b-actin at 1/5,000 (Calbiochem). Secondary antibodies:
Alexa-680 mouse anti-IgG at 1/15,000 (Invitrogen); Alexa-800 mouse anti-IgM at
1/15,000 (Rockland); Alexa-800 rabbit anti-IgG at 1/15,000 (Rockland).
Signal quantification
Membranes were scanned and quantified using an Odyssey infra-red scanner
(Licor Biosciences) and Prism 5 software (GraphPad).
Normalisation of Tau levels between membranes
A constant amount of recombinant Tau was included in an individual lane on each
Tau protein gel to act as a normalisation control.
Statistical analysis
Statistical analysis was performed using Prism 5 (GraphPad). Transcript and
protein quantification data were analysed for significance by one-way ANOVA
with Bonferroni correction. Resulting p values lower than 0.05 were deemed
significant.
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